Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy.
Little is known of the changes in human immunodeficiency virus type 1 (HIV-1)-specific effector cytotoxic T lymphocytes (CTL) after potent antiretroviral therapy. Using HLA/peptide tetrameric complexes, we show that after starting treatment, there are early rapid fluctuations in the HIV-1-specific C...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1999
|
| _version_ | 1826299109196169216 |
|---|---|
| author | Ogg, G Jin, X Bonhoeffer, S Moss, P Nowak, M Monard, S Segal, J Cao, Y Rowland-Jones, S Hurley, A Markowitz, M Ho, D Mcmichael, A Nixon, D |
| author_facet | Ogg, G Jin, X Bonhoeffer, S Moss, P Nowak, M Monard, S Segal, J Cao, Y Rowland-Jones, S Hurley, A Markowitz, M Ho, D Mcmichael, A Nixon, D |
| author_sort | Ogg, G |
| collection | OXFORD |
| description | Little is known of the changes in human immunodeficiency virus type 1 (HIV-1)-specific effector cytotoxic T lymphocytes (CTL) after potent antiretroviral therapy. Using HLA/peptide tetrameric complexes, we show that after starting treatment, there are early rapid fluctuations in the HIV-1-specific CTL response which last 1 to 2 weeks. These fluctuations are followed by an exponential decay (median half-life, 45 days) of HIV-1-specific CTL which continues while viremia remains undetectable. These data have implications for the immunological control of drug-resistant virus. |
| first_indexed | 2024-03-07T04:56:55Z |
| format | Journal article |
| id | oxford-uuid:d6e91788-bbd5-4209-ba2b-bd89a33b5c8d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:56:55Z |
| publishDate | 1999 |
| record_format | dspace |
| spelling | oxford-uuid:d6e91788-bbd5-4209-ba2b-bd89a33b5c8d2022-03-27T08:37:09ZDecay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d6e91788-bbd5-4209-ba2b-bd89a33b5c8dEnglishSymplectic Elements at Oxford1999Ogg, GJin, XBonhoeffer, SMoss, PNowak, MMonard, SSegal, JCao, YRowland-Jones, SHurley, AMarkowitz, MHo, DMcmichael, ANixon, DLittle is known of the changes in human immunodeficiency virus type 1 (HIV-1)-specific effector cytotoxic T lymphocytes (CTL) after potent antiretroviral therapy. Using HLA/peptide tetrameric complexes, we show that after starting treatment, there are early rapid fluctuations in the HIV-1-specific CTL response which last 1 to 2 weeks. These fluctuations are followed by an exponential decay (median half-life, 45 days) of HIV-1-specific CTL which continues while viremia remains undetectable. These data have implications for the immunological control of drug-resistant virus. |
| spellingShingle | Ogg, G Jin, X Bonhoeffer, S Moss, P Nowak, M Monard, S Segal, J Cao, Y Rowland-Jones, S Hurley, A Markowitz, M Ho, D Mcmichael, A Nixon, D Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. |
| title | Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. |
| title_full | Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. |
| title_fullStr | Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. |
| title_full_unstemmed | Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. |
| title_short | Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. |
| title_sort | decay kinetics of human immunodeficiency virus specific effector cytotoxic t lymphocytes after combination antiretroviral therapy |
| work_keys_str_mv | AT oggg decaykineticsofhumanimmunodeficiencyvirusspecificeffectorcytotoxictlymphocytesaftercombinationantiretroviraltherapy AT jinx decaykineticsofhumanimmunodeficiencyvirusspecificeffectorcytotoxictlymphocytesaftercombinationantiretroviraltherapy AT bonhoeffers decaykineticsofhumanimmunodeficiencyvirusspecificeffectorcytotoxictlymphocytesaftercombinationantiretroviraltherapy AT mossp decaykineticsofhumanimmunodeficiencyvirusspecificeffectorcytotoxictlymphocytesaftercombinationantiretroviraltherapy AT nowakm decaykineticsofhumanimmunodeficiencyvirusspecificeffectorcytotoxictlymphocytesaftercombinationantiretroviraltherapy AT monards decaykineticsofhumanimmunodeficiencyvirusspecificeffectorcytotoxictlymphocytesaftercombinationantiretroviraltherapy AT segalj decaykineticsofhumanimmunodeficiencyvirusspecificeffectorcytotoxictlymphocytesaftercombinationantiretroviraltherapy AT caoy decaykineticsofhumanimmunodeficiencyvirusspecificeffectorcytotoxictlymphocytesaftercombinationantiretroviraltherapy AT rowlandjoness decaykineticsofhumanimmunodeficiencyvirusspecificeffectorcytotoxictlymphocytesaftercombinationantiretroviraltherapy AT hurleya decaykineticsofhumanimmunodeficiencyvirusspecificeffectorcytotoxictlymphocytesaftercombinationantiretroviraltherapy AT markowitzm decaykineticsofhumanimmunodeficiencyvirusspecificeffectorcytotoxictlymphocytesaftercombinationantiretroviraltherapy AT hod decaykineticsofhumanimmunodeficiencyvirusspecificeffectorcytotoxictlymphocytesaftercombinationantiretroviraltherapy AT mcmichaela decaykineticsofhumanimmunodeficiencyvirusspecificeffectorcytotoxictlymphocytesaftercombinationantiretroviraltherapy AT nixond decaykineticsofhumanimmunodeficiencyvirusspecificeffectorcytotoxictlymphocytesaftercombinationantiretroviraltherapy |